Existing Annotations Review

GO Term	Evidence	Action	Reason
GO:0006508 proteolysis	IBA GO_REF:0000033	ACCEPT	Summary: proteolysis (GO:0006508) is supported for Tpp1. Falcon deep research confirms zebrafish Tpp1 is a lysosomal sedolisin-family serine protease contributing to lysosomal proteolysis/proteostasis. Reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis. Supporting Evidence: file:DANRE/tpp1/tpp1-uniprot.txt Lysosomal serine protease with tripeptidyl-peptidase I file:DANRE/tpp1/tpp1-uniprot.txt Release of an N-terminal tripeptide file:DANRE/tpp1/tpp1-uniprot.txt SUBCELLULAR LOCATION: Lysosome PMID:23587805 deficient in tripeptidyl peptidase 1 file:DANRE/tpp1/tpp1-deep-research-falcon.md Tpp1 contributes to lysosomal proteolysis/proteostasis
GO:0008240 tripeptidyl-peptidase activity	IBA GO_REF:0000033	ACCEPT	Summary: tripeptidyl-peptidase activity (GO:0008240) is supported for Tpp1 and is its core molecular function. Falcon deep research confirms zebrafish Tpp1 acts mainly as an N-terminal exopeptidase releasing tripeptides, assayed with the fluorogenic substrate Arg-Ala-Phe-ACC at acidic pH. Reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis. Supporting Evidence: file:DANRE/tpp1/tpp1-uniprot.txt Lysosomal serine protease with tripeptidyl-peptidase I file:DANRE/tpp1/tpp1-uniprot.txt Release of an N-terminal tripeptide file:DANRE/tpp1/tpp1-uniprot.txt SUBCELLULAR LOCATION: Lysosome PMID:23587805 deficient in tripeptidyl peptidase 1 file:DANRE/tpp1/tpp1-deep-research-falcon.md tpp1 encodes lysosomal tripeptidyl-peptidase 1 (EC 3.4.14.9), a sedolisin-family serine protease that acts mainly as an N-terminal exopeptidase file:DANRE/tpp1/tpp1-deep-research-falcon.md cleavage of the fluorogenic tripeptidyl substrate Arg-Ala-Phe-ACC at acidic pH (pH 4.0)
GO:0004175 endopeptidase activity	IBA GO_REF:0000033	KEEP AS NON CORE	Summary: endopeptidase activity (GO:0004175) is a supported but broad parent term for Tpp1. Falcon deep research confirms Tpp1 acts mainly as an N-terminal exopeptidase with only limited endopeptidase activity, so this broad term is retained as non-core. Reason: The more informative tripeptidyl-peptidase and serine-type peptidase activities are reviewed separately; this parent term is retained as non-core to reduce redundancy. Supporting Evidence: file:DANRE/tpp1/tpp1-uniprot.txt Lysosomal serine protease with tripeptidyl-peptidase I file:DANRE/tpp1/tpp1-uniprot.txt Release of an N-terminal tripeptide file:DANRE/tpp1/tpp1-uniprot.txt SUBCELLULAR LOCATION: Lysosome PMID:23587805 deficient in tripeptidyl peptidase 1 file:DANRE/tpp1/tpp1-deep-research-falcon.md removing tripeptides from the N-termini of polypeptide substrates, with some limited endopeptidase activity
GO:0007417 central nervous system development	IBA GO_REF:0000033	KEEP AS NON CORE	Summary: central nervous system development (GO:0007417) is supported as a phenotype of Tpp1 deficiency but is not the core molecular role. Falcon deep research describes early-onset progressive neurodegeneration of the retina, optic tectum and cerebellum in tpp1 mutants, consistent with a downstream consequence of impaired lysosomal proteolysis. Reason: The direct conserved role is lysosomal tripeptidyl-peptidase/proteolysis; neurodevelopmental and locomotor defects are downstream phenotypes. Supporting Evidence: PMID:23587805 displays progressive neurodegeneration PMID:23587805 functional motor impairment file:DANRE/tpp1/tpp1-deep-research-falcon.md early-onset, progressive neurodegenerative phenotype with prominent defects in retina, optic tectum, and cerebellum
GO:0004252 serine-type endopeptidase activity	IEA GO_REF:0000002	KEEP AS NON CORE	Summary: serine-type endopeptidase activity (GO:0004252) is a broad term for Tpp1 that asserts endopeptidase specificity. Falcon deep research confirms Tpp1 is a serine protease with a sedolisin-family catalytic triad (Glu-Asp-Ser), but it acts mainly as an N-terminal exopeptidase with only limited endopeptidase activity. This IEA annotation derives from the Peptidase_S8/S53 superfamily fold (InterPro IPR036852), which spans both endo- and exo-peptidases, so the automatic domain mapping does not accurately reflect CLN2/Tpp1's primary exopeptidase specificity. The serine-type peptidase activity (GO:0008236) parent is more accurate, and the specific tripeptidyl-peptidase activity (GO:0008240) is the core function. Retained as non-core, consistent with the endopeptidase activity (GO:0004175) parent term. Reason: Tpp1 is primarily an exopeptidase with only limited endopeptidase activity; this endopeptidase-specific IEA term (from the broad Peptidase_S8/S53 fold) overstates the specificity and is retained as non-core, consistent with the GO:0004175 endopeptidase activity parent. Supporting Evidence: file:DANRE/tpp1/tpp1-uniprot.txt Lysosomal serine protease with tripeptidyl-peptidase I file:DANRE/tpp1/tpp1-uniprot.txt Release of an N-terminal tripeptide file:DANRE/tpp1/tpp1-uniprot.txt SUBCELLULAR LOCATION: Lysosome PMID:23587805 deficient in tripeptidyl peptidase 1 file:DANRE/tpp1/tpp1-deep-research-falcon.md removing tripeptides from the N-termini of polypeptide substrates, with some limited endopeptidase activity file:DANRE/tpp1/tpp1-deep-research-falcon.md catalytic triad consistent with sedolisin-family enzymes (reported as Glu–Asp–Ser
GO:0005764 lysosome	IEA GO_REF:0000044	ACCEPT	Summary: lysosome (GO:0005764) is supported for Tpp1. Falcon deep research confirms the enzyme is targeted to and functions in the lysosome, predicted to be delivered after removal of a 19-aa signal peptide via the mannose-6-phosphate pathway. Reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis. Supporting Evidence: file:DANRE/tpp1/tpp1-uniprot.txt Lysosomal serine protease with tripeptidyl-peptidase I file:DANRE/tpp1/tpp1-uniprot.txt Release of an N-terminal tripeptide file:DANRE/tpp1/tpp1-uniprot.txt SUBCELLULAR LOCATION: Lysosome PMID:23587805 deficient in tripeptidyl peptidase 1 file:DANRE/tpp1/tpp1-deep-research-falcon.md the enzyme is targeted to and functions in the lysosome
GO:0006508 proteolysis	IEA GO_REF:0000002	ACCEPT	Summary: proteolysis (GO:0006508) is supported for Tpp1 (InterPro-derived). Falcon deep research confirms Tpp1 contributes to lysosomal proteolysis/proteostasis; loss yields lysosomal storage of undegraded material. Note that the more specific GO:1905146 (lysosomal protein catabolic process) would more precisely capture Tpp1's biological role within the lysosome; GO:0006508 is retained here as the directly annotated, conservative term. Reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis. Supporting Evidence: file:DANRE/tpp1/tpp1-uniprot.txt Lysosomal serine protease with tripeptidyl-peptidase I file:DANRE/tpp1/tpp1-uniprot.txt Release of an N-terminal tripeptide file:DANRE/tpp1/tpp1-uniprot.txt SUBCELLULAR LOCATION: Lysosome PMID:23587805 deficient in tripeptidyl peptidase 1 file:DANRE/tpp1/tpp1-deep-research-falcon.md Tpp1 contributes to lysosomal proteolysis/proteostasis
GO:0008236 serine-type peptidase activity	IEA GO_REF:0000002	MODIFY	Summary: serine-type peptidase activity (GO:0008236) is correct but less specific than tripeptidyl-peptidase activity. Falcon deep research confirms the informative function is N-terminal tripeptidyl exopeptidase cleavage, so the more specific GO:0008240 is preferred. Reason: The specific molecular function is tripeptidyl-peptidase activity. Proposed replacements: tripeptidyl-peptidase activity Supporting Evidence: file:DANRE/tpp1/tpp1-uniprot.txt Lysosomal serine protease with tripeptidyl-peptidase I file:DANRE/tpp1/tpp1-uniprot.txt Release of an N-terminal tripeptide file:DANRE/tpp1/tpp1-uniprot.txt SUBCELLULAR LOCATION: Lysosome PMID:23587805 deficient in tripeptidyl peptidase 1 file:DANRE/tpp1/tpp1-deep-research-falcon.md tpp1 encodes lysosomal tripeptidyl-peptidase 1 (EC 3.4.14.9), a sedolisin-family serine protease that acts mainly as an N-terminal exopeptidase
GO:0005764 lysosome	ISS GO_REF:0000024	ACCEPT	Summary: lysosome (GO:0005764) is supported for Tpp1 by orthology to human TPP1/O14773. Falcon deep research corroborates lysosomal localization, with loss producing enlarged/hypertrophic lysosomes and SCMAS storage. Reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis. Supporting Evidence: file:DANRE/tpp1/tpp1-uniprot.txt Lysosomal serine protease with tripeptidyl-peptidase I file:DANRE/tpp1/tpp1-uniprot.txt Release of an N-terminal tripeptide file:DANRE/tpp1/tpp1-uniprot.txt SUBCELLULAR LOCATION: Lysosome PMID:23587805 deficient in tripeptidyl peptidase 1 file:DANRE/tpp1/tpp1-deep-research-falcon.md lysosomal storage phenotypes including enlarged/hypertrophic lysosomes
GO:0007417 central nervous system development	IMP PMID:23587805 A zebrafish model of CLN2 disease is deficient in tripeptidy...	KEEP AS NON CORE	Summary: central nervous system development (GO:0007417) is supported as a phenotype of Tpp1 deficiency (zebrafish IMP) but is not the core molecular role. Falcon deep research describes progressive neurodegeneration of the retina, optic tectum and cerebellum in tpp1 mutants. Reason: The direct conserved role is lysosomal tripeptidyl-peptidase/proteolysis; neurodevelopmental and locomotor defects are downstream phenotypes. Supporting Evidence: PMID:23587805 displays progressive neurodegeneration PMID:23587805 functional motor impairment file:DANRE/tpp1/tpp1-deep-research-falcon.md early-onset, progressive neurodegenerative phenotype with prominent defects in retina, optic tectum, and cerebellum
GO:0007626 locomotory behavior	IMP PMID:23587805 A zebrafish model of CLN2 disease is deficient in tripeptidy...	KEEP AS NON CORE	Summary: locomotory behavior (GO:0007626) is supported as a phenotype of Tpp1 deficiency (zebrafish IMP) but is not the core molecular role. Falcon deep research notes a phase of increased locomotion consistent with seizures followed by progressive motor impairment. Reason: The direct conserved role is lysosomal tripeptidyl-peptidase/proteolysis; neurodevelopmental and locomotor defects are downstream phenotypes. Supporting Evidence: PMID:23587805 displays progressive neurodegeneration PMID:23587805 functional motor impairment file:DANRE/tpp1/tpp1-deep-research-falcon.md phase of increased locomotion consistent with seizures
GO:0022008 neurogenesis	IMP PMID:23587805 A zebrafish model of CLN2 disease is deficient in tripeptidy...	KEEP AS NON CORE	Summary: neurogenesis (GO:0022008) is supported as a phenotype of Tpp1 deficiency (zebrafish IMP) but is not the core molecular role. PMID:23587805 reports that secondary neurogenesis in the retina, optic tectum and cerebellum is impaired in tpp1 mutant zebrafish, and falcon deep research notes a sustained reduction in proliferation affecting the retina and midbrain-hindbrain boundary. Reason: The direct conserved role is lysosomal tripeptidyl-peptidase/proteolysis; neurodevelopmental and locomotor defects are downstream phenotypes. Supporting Evidence: PMID:23587805 Secondary neurogenesis in the file:DANRE/tpp1/tpp1-deep-research-falcon.md sustained reduction in proliferation
GO:0008240 tripeptidyl-peptidase activity	ISS PMID:14609438 A model of tripeptidyl-peptidase I (CLN2), a ubiquitous and ...	ACCEPT	Summary: tripeptidyl-peptidase activity (GO:0008240) is supported for Tpp1 by sequence similarity to the highly conserved sedolisin-family CLN2/TPP-I enzymes. Falcon deep research confirms zebrafish Tpp1 acts mainly as an N-terminal exopeptidase releasing tripeptides. Reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis. Supporting Evidence: file:DANRE/tpp1/tpp1-uniprot.txt Lysosomal serine protease with tripeptidyl-peptidase I file:DANRE/tpp1/tpp1-uniprot.txt Release of an N-terminal tripeptide file:DANRE/tpp1/tpp1-uniprot.txt SUBCELLULAR LOCATION: Lysosome PMID:23587805 deficient in tripeptidyl peptidase 1 file:DANRE/tpp1/tpp1-deep-research-falcon.md removing tripeptides from the N-termini of polypeptide substrates, with some limited endopeptidase activity

Core Functions

tpp1 acts in the lysosome as tripeptidyl-peptidase 1, releasing N-terminal tripeptides during lysosomal protein catabolism.

Molecular Function:

tripeptidyl-peptidase activity

Directly Involved In:

proteolysis

Cellular Locations:

lysosome

Supporting Evidence:

file:DANRE/tpp1/tpp1-uniprot.txt
Lysosomal serine protease with tripeptidyl-peptidase I
file:DANRE/tpp1/tpp1-uniprot.txt
Release of an N-terminal tripeptide
file:DANRE/tpp1/tpp1-uniprot.txt
SUBCELLULAR LOCATION: Lysosome
PMID:23587805
deficient in tripeptidyl peptidase 1
file:DANRE/tpp1/tpp1-deep-research-falcon.md
tpp1 encodes lysosomal tripeptidyl-peptidase 1 (EC 3.4.14.9), a sedolisin-family serine protease that acts mainly as an **N-terminal exopeptidase**

References

GO_REF:0000002

Gene Ontology annotation through association of InterPro records with GO terms

GO_REF:0000024

Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity

GO_REF:0000033

Annotation inferences using phylogenetic trees

GO_REF:0000044

Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt

PMID:14609438

A model of tripeptidyl-peptidase I (CLN2), a ubiquitous and highly conserved member of the sedolisin family of serine-carboxyl peptidases.

TPP-I/CLN2 is a member of the sedolisin family of serine-carboxyl peptidases, and its loss causes a fatal neurodegenerative disease (late-infantile neuronal ceroid lipofuscinosis).

"defects in expression of this enzyme lead to a fatal neurodegenerative disease"
CLN2 orthologs are highly conserved and widely distributed across eukaryotes, including closely related but distinct enzymes present in fish such as zebrafish.

"Closely related, although clearly distinct, enzymes are present in fish"

PMID:23587805

A zebrafish model of CLN2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation.

Homozygous tpp1(sa0011) mutant zebrafish are deficient in tripeptidyl peptidase 1 and display a severe, progressive, early onset neurodegenerative phenotype.

"deficient in tripeptidyl peptidase 1 and"
As in human CLN2 patients, the mutant zebrafish store subunit c of mitochondrial ATP-synthase and develop hypertrophic lysosomes with localized apoptotic cell death in the retina, optic tectum and cerebellum.

"storage of subunit c"
Secondary neurogenesis in the retina, optic tectum and cerebellum is impaired in tpp1 mutant zebrafish.

"Secondary neurogenesis in the"
The neurodegenerative phenotype results in functional motor impairment preceded by a phase of seizure-like hyperactivity.

"functional motor impairment"

file:DANRE/tpp1/tpp1-uniprot.txt

UniProtKB entry F8W2M8 for Danio rerio tpp1

UniProt describes Tpp1 as a lysosomal serine protease with tripeptidyl-peptidase I activity that releases an N-terminal tripeptide from a polypeptide but also has endopeptidase activity (EC 3.4.14.9).

"Lysosomal serine protease with tripeptidyl-peptidase I"
Tpp1 is localized to the lysosome and is activated by autocatalytic proteolytic processing from a precursor zymogen.

"SUBCELLULAR LOCATION: Lysosome"

file:DANRE/tpp1/tpp1-deep-research-falcon.md

Falcon deep research synthesis for Danio rerio tpp1 (tripeptidyl-peptidase 1 / CLN2)

Zebrafish tpp1 encodes lysosomal tripeptidyl-peptidase 1 (EC 3.4.14.9), a sedolisin (S53)-family serine protease that acts mainly as an N-terminal exopeptidase releasing tripeptides, with limited endopeptidase activity.

"tpp1 encodes lysosomal tripeptidyl-peptidase 1 (EC 3.4.14.9), a sedolisin-family serine protease that acts mainly as an **N-terminal exopeptidase**"
The TPP1 catalytic triad is consistent with sedolisin-family enzymes, reported as Glu-Asp-Ser, distinguishing it from classical Ser-His-Asp serine proteases.

"catalytic triad consistent with sedolisin-family enzymes (reported as **Glu–Asp–Ser**"
Zebrafish Tpp1 is predicted to be targeted to the lysosome after removal of a 19-aa signal peptide and is trafficked to lysosomes via the mannose-6-phosphate pathway.

"predicted to be targeted to the lysosome after removal of a 19-aa signal peptide"
Tpp1 activity in zebrafish embryos is measured as cleavage of the fluorogenic tripeptidyl substrate Arg-Ala-Phe-ACC at acidic pH (pH 4.0), consistent with a lysosomal enzyme, and is significantly reduced in tpp1(sa0011) mutants.

"cleavage of the fluorogenic tripeptidyl substrate **Arg-Ala-Phe-ACC** at **acidic pH (pH 4.0)**"
Loss of Tpp1 produces classic lysosomal storage phenotypes including enlarged/hypertrophic lysosomes and accumulation of subunit c of mitochondrial ATP synthase (SCMAS), positioning Tpp1 within lysosome-dependent proteostasis and degradative pathways.

"lysosomal storage phenotypes including **enlarged/hypertrophic lysosomes**"
Homozygous tpp1(sa0011) mutants show an early-onset, progressive neurodegenerative phenotype with defects in retina, optic tectum and cerebellum, increased apoptosis, sustained reduction in proliferation, seizure-like hyperactivity, and motor decline.

"early-onset, progressive neurodegenerative phenotype with prominent defects in **retina**, **optic tectum**, and **cerebellum**"

Suggested Experiments

Experiment: Generate a tpp1 null line by CRISPR/Cas9, then assay lysosomal tripeptidyl-peptidase activity in larval/adult brain lysates against a fluorogenic Ala-Ala-Phe substrate and quantify ceroid-lipofuscin storage histologically.

Hypothesis: Loss of zebrafish tpp1 abolishes lysosomal tripeptidyl-peptidase activity and leads to accumulation of autofluorescent storage material in neurons.

Type: CRISPR knockout

Experiment: Express and purify the Tpp1 proenzyme, incubate across a range of pH values (acidic lysosomal versus neutral), and monitor proteolytic processing and gain of exopeptidase activity over time by SDS-PAGE and activity assays.

Hypothesis: Recombinant zebrafish Tpp1 is produced as an inactive zymogen that undergoes autocatalytic activation upon exposure to acidic pH.

Type: tripeptidyl-peptidase activity assay

Experiment: Reintroduce wild-type or catalytically dead tpp1 mRNA/transgene into tpp1 mutants and assess rescue of progressive neurodegeneration, neuronal proliferation, and swimming behavior alongside lipofuscin storage load.

Hypothesis: Restoring Tpp1 enzymatic activity in tpp1-deficient zebrafish rescues neurodegeneration and locomotor defects.

Type: lipofuscin/storage-material histology

Deep Research

Falcon

(tpp1-deep-research-falcon.md)

Research Report: Functional Annotation of **tpp1** (UniProt **F8W2M8**) in *Danio rerio* (zebrafish) Falcon Edison Scientific Literature 24 citations 2 artifacts 2026-05-31T17:09:49.914642

Edison artifact artifact-00 (text/markdown)

## Context ID: pqac-00000021 The document provides comprehensive characterization of the zebrafish *tpp1(sa0011)* mutant, which serves as a model for CLN2 disea (image/png)

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research Report: Functional Annotation of tpp1 (UniProt F8W2M8) in Danio rerio (zebrafish)

0) Target verification (critical disambiguation)

The target is Danio rerio tpp1, encoding tripeptidyl-peptidase 1 (TPP1/TPP-1; EC 3.4.14.9), a lysosomal serine protease of the sedolisin (S53) lineage. A primary zebrafish study explicitly identifies zebrafish tpp1 (Ensembl ENSDARG00000042793) as homologous to human TPP1/CLN2 and characterizes a loss-of-function allele (tpp1sa0011) with loss of enzyme activity and lysosomal storage phenotypes, matching the UniProt description and expected domain class (sedolisin/Peptidase_S8/S53). (mahmood2013azebrafishmodel pages 2-2, mahmood2013azebrafishmodel pages 2-3)

1) Key concepts and definitions (current understanding)

1.1 What TPP1 is

TPP1 is a lysosomal serine protease that functions primarily as an N-terminal exopeptidase, removing tripeptides from the N-termini of polypeptide substrates, with some limited endopeptidase activity. (mahmood2013azebrafishmodel pages 2-3)

1.2 Enzyme classification and catalytic mechanism

TPP1 is annotated as EC 3.4.14.9. Mechanistically, it is described as a serine protease with a catalytic triad consistent with sedolisin-family enzymes (reported as Glu–Asp–Ser in the vertebrate TPP1 literature summarized in the zebrafish model paper). (mahmood2013azebrafishmodel pages 2-3)

1.3 Processing, maturation, and lysosomal targeting

In vertebrates, TPP1 is synthesized as a higher-molecular-weight precursor (~66–68 kDa) that is proteolytically processed to a mature (~46–48 kDa) lysosomal enzyme, and is trafficked to lysosomes via the mannose-6-phosphate pathway (a standard lysosomal hydrolase targeting route described in the zebrafish CLN2 model paper). (mahmood2013azebrafishmodel pages 2-3)

For zebrafish specifically, tpp1 encodes a 557-aa pro-peptide derived from 13 exons, and is predicted to be targeted to the lysosome after removal of a 19-aa signal peptide. (mahmood2013azebrafishmodel pages 2-2)

2) Zebrafish tpp1 molecular function and evidence (biochemistry-oriented)

2.1 Substrate specificity and how it is measured experimentally in zebrafish

A practical operational definition of Tpp1 activity in zebrafish embryos is cleavage of the fluorogenic tripeptidyl substrate Arg-Ala-Phe-ACC at acidic pH (pH 4.0), consistent with a lysosomal enzyme. (mahmood2013azebrafishmodel pages 5-6, mahmood2013azebrafishmodel pages 3-4)

Assay parameters reported for zebrafish embryos (96 hpf) include: homogenization in buffer (150 mM NaCl, 100 mM sodium citrate, 1 g/L Triton X-100, pH 4.0), addition of crude protein to 0.25 mM Arg-Ala-Phe-ACC in a 50 µL reaction, incubation 90 min, and termination with SDS. (mahmood2013azebrafishmodel pages 3-4)

2.2 Evidence of loss-of-function in zebrafish mutants

In the tpp1sa0011 homozygous zebrafish model, Tpp1 enzymatic activity is significantly reduced in embryo extracts using the Arg-Ala-Phe-ACC assay. (mahmood2013azebrafishmodel pages 5-6)

3) Cellular localization and pathway context in zebrafish

3.1 Subcellular site of action

TPP1 is a lysosomal protease; the zebrafish model emphasizes lysosomal pathology and storage consistent with loss of lysosomal proteolytic capacity. (mahmood2013azebrafishmodel pages 2-3)

The authors note an important experimental nuance: maternally derived Tpp1 may persist early and be present in lysosomes, while a zygotically derived mutant product lacking a signal sequence would fail to reach lysosomes. (mahmood2013azebrafishmodel pages 5-6)

3.2 Pathway context: lysosomal proteostasis and storage pathology

Loss of Tpp1 produces classic lysosomal storage phenotypes including enlarged/hypertrophic lysosomes and storage material accumulation, positioning Tpp1 within lysosome-dependent proteostasis and degradative pathways. (mahmood2013azebrafishmodel pages 2-3)

A widely used biomarker in CLN2/TPP1 deficiency models is accumulation of subunit c of mitochondrial ATP synthase (SCMAS) as storage material, which is reported as a hallmark in the zebrafish model. (mahmood2013azebrafishmodel pages 16-17, mahmood2013azebrafishmodel pages 1-2)

4) Zebrafish loss-of-function phenotypes (organism-level functional annotation)

4.1 Neurodegeneration and retinal degeneration

Homozygous tpp1sa0011 mutants show an early-onset, progressive neurodegenerative phenotype with prominent defects in retina, optic tectum, and cerebellum. (mahmood2013azebrafishmodel pages 1-2, mahmood2013azebrafishmodel pages 16-17)

4.2 Cell death and reduced proliferation

Mutants show an early increase in apoptosis (assayed by TUNEL) and a sustained reduction in proliferation, particularly affecting the retina and midbrain–hindbrain boundary. (mahmood2013azebrafishmodel pages 16-17, mahmood2013azebrafishmodel pages 3-4)

4.3 Axon tract and motor phenotypes; seizure-like behavior

The zebrafish model reports disorganization of axon pathways (e.g., optic nerve and spinal motor nerves) and behavioral phenotypes featuring a phase of increased locomotion consistent with seizures, followed by progressive motor impairment. (mahmood2013azebrafishmodel pages 2-3, mahmood2013azebrafishmodel pages 1-2)

4.4 Survival statistics (zebrafish)

The zebrafish model reports markedly shortened survival, with mutants dying in early larval stages (reported as reduced median survival around 5 dpf in the phenotype summary, and survival curves extending to death by approximately 8 dpf in figure-based summaries). (mahmood2013azebrafishmodel pages 1-2, mahmood2013azebrafishmodel media 97a62347)

Visual evidence from the primary zebrafish paper

The primary zebrafish study contains figure/table panels summarizing reduced Tpp1 enzymatic activity, survival curves, retinal degeneration quantification, and lysosomal enlargement, and a comparative table of cross-species CLN2 features. (mahmood2013azebrafishmodel media 97a62347, mahmood2013azebrafishmodel media a79a33ad, mahmood2013azebrafishmodel media e597a90c, mahmood2013azebrafishmodel media 008308d6)

5) Current applications and real-world implementations

5.1 Zebrafish as a disease-model platform for CLN2/TPP1 biology

The zebrafish tpp1 loss-of-function line is positioned as a tractable vertebrate model for lysosomal storage disease biology, with quantifiable endpoints (SCMAS storage, lysosome size, apoptosis/proliferation, and automated locomotion assays) that can be used for mechanistic studies and compound screening. (mahmood2013azebrafishmodel pages 2-3, mahmood2013azebrafishmodel pages 1-2)

5.2 Clinical implementation: enzyme replacement therapy for CLN2 (human translational context)

Although the user’s gene target is zebrafish, TPP1 is directly actionable clinically in humans: CLN2 disease is caused by TPP1 deficiency, and enzyme replacement therapy (ERT) with cerliponase alfa (recombinant human TPP1) is implemented by intracerebroventricular administration because recombinant enzyme does not cross the blood–brain barrier. (takahashi2024investigatingtheinvolvement pages 16-20)

5.3 Addressing retinal disease: intravitreal rhTPP1 (2024)

A key 2024 development is a first-in-human study testing intravitreal rhTPP1 for CLN2-associated retinopathy, motivated by the limitation that intracerebroventricular ERT slows neurologic decline but does not prevent retinal dystrophy. In the reported single-center compassionate-use protocol, 8 children (ages 5–9) received unilateral intravitreal rhTPP1 (right eye) with the left eye as paired control; dosing included 0.2 mg in 0.05 mL injections and follow-up over 12–18 months. (wawrzynski2024firstinman pages 1-2, wawrzynski2024firstinman pages 2-3)

6) Expert opinions / authoritative guidance (2023–2024 prioritized)

6.1 2023 Brazilian expert consensus (diagnosis and management)

A 2023 Brazilian expert consensus (nine pediatric neurologists; 92-question panel) emphasizes that CLN2 should be suspected in children roughly 2–4 years old presenting with language delay/regression and new-onset epilepsy, and recommends EEG and MRI as key investigations, with confirmatory TPP1 enzyme activity testing plus biallelic pathogenic variants for diagnosis and to enable ERT prescribing. (sampaio2023clinicalmanagementand pages 1-2, sampaio2023clinicalmanagementand pages 6-7, sampaio2023clinicalmanagementand pages 3-6)

This consensus also provides practical clinical-management recommendations (e.g., antiseizure and symptomatic management approaches), and highlights system-level barriers such as limited access to genetic testing in some settings, reinforcing that therapeutic availability increases the value of early diagnosis. (sampaio2023clinicalmanagementand pages 1-2, sampaio2023clinicalmanagementand pages 10-11)

6.2 Expert framing of ERT limitations

Expert summaries emphasize that cerliponase alfa requires intracerebroventricular delivery due to blood–brain barrier limitations and that, even with ERT, progressive neurological features (including difficult-to-control seizures) remain a major unmet need. (takahashi2024investigatingtheinvolvement pages 16-20)

7) Relevant recent statistics and quantitative findings (recent studies emphasized)

7.1 Real-world safety signals for cerliponase alfa (2024)

A 2024 analysis of spontaneous reports and open-label study safety data summarized outcomes in 38 children (ages 1–9) treated with cerliponase alfa, with follow-up up to 309 weeks. Reported frequencies included: convulsion-related events in 31/38 (82%) patients (with only 4% of convulsion events judged drug-related) and hypersensitivity in 19/38 (50%) (including 6 CTCAE grade 3 reactions without discontinuations). (ammendolia2024adversereactionsto pages 7-10)

7.2 Intravitreal rhTPP1 retinal outcomes (2024)

In the 2024 intravitreal rhTPP1 report, among the subgroup with progressive retinal thinning, the mean decline rates in paracentral macular volume were approximately 0.168 mm³/year (treated) vs 0.254 mm³/year (untreated), and no severe inflammatory ocular adverse events (uveitis/media opacity/sustained IOP rise) were observed; however, notable procedure-related events included transient central retinal artery occlusions in two patients requiring intervention. (wawrzynski2024firstinman pages 2-3)

8) Summary interpretation for functional annotation (zebrafish-focused)

Primary molecular function: zebrafish Tpp1 is a lysosomal, acid-active sedolisin-family serine protease whose core activity is tripeptidyl N-terminal exopeptidase cleavage, experimentally assayed using fluorogenic tripeptide substrates (e.g., Arg-Ala-Phe-ACC). (mahmood2013azebrafishmodel pages 2-3, mahmood2013azebrafishmodel pages 3-4)

Subcellular localization: the enzyme is targeted to and functions in the lysosome, supported by predicted signal peptide and lysosomal storage phenotypes when absent. (mahmood2013azebrafishmodel pages 2-2, mahmood2013azebrafishmodel pages 2-3)

Pathway and biological process context: Tpp1 contributes to lysosomal proteolysis/proteostasis; loss of function yields lysosomal enlargement and storage material accumulation (including SCMAS), consistent with impaired lysosomal degradation. (mahmood2013azebrafishmodel pages 16-17, mahmood2013azebrafishmodel pages 1-2)

Organism-level role and phenotypes: in zebrafish, tpp1 loss causes early developmental/larval onset retinal and CNS degeneration, increased apoptosis, reduced proliferation, seizure-like hyperactivity and motor deficits, and early lethality—making it a practical whole-organism platform for mechanistic studies and screening. (mahmood2013azebrafishmodel pages 1-2, mahmood2013azebrafishmodel pages 16-17, mahmood2013azebrafishmodel pages 2-3)

Evidence summary table

Category	Key points	Best supporting citations
Enzyme activity / substrate	- tpp1 encodes lysosomal tripeptidyl-peptidase 1 (EC 3.4.14.9), a sedolisin-family serine protease that acts mainly as an N-terminal exopeptidase releasing tripeptides, with limited endopeptidase activity. - Conserved catalytic residues reported for zebrafish/homologous TPP1 include Glu, Asp, Ser; zebrafish protein is homologous to human TPP1 and was assayed with the fluorogenic substrate Arg-Ala-Phe-ACC. - In zebrafish mutants, Tpp1 activity is significantly reduced in embryo extracts, supporting true loss of enzymatic function.	(mahmood2013azebrafishmodel pages 2-3, mahmood2013azebrafishmodel pages 5-6, mahmood2013azebrafishmodel pages 2-2, mahmood2013azebrafishmodel pages 3-4)
Processing & localization	- Zebrafish Tpp1 is a 557 aa precursor encoded by 13 exons and is predicted to enter the secretory pathway via a 19 aa signal peptide before lysosomal delivery. - TPP1 is synthesized as a ~66–68 kDa precursor and processed to a ~46–48 kDa mature enzyme; trafficking is via the mannose-6-phosphate pathway in vertebrate TPP1 literature. - Mahmood et al. note maternally derived Tpp1 persists in lysosomes early, whereas a zygotically derived mutant product lacking signal sequence would fail to reach lysosomes.	(mahmood2013azebrafishmodel pages 2-3, mahmood2013azebrafishmodel pages 5-6, mahmood2013azebrafishmodel pages 2-2)
Zebrafish LOF phenotypes & biomarkers	- Homozygous tpp1sa0011 zebrafish show early progressive neurodegeneration: small retina/head, curved body, absent swim bladder, retinal/cerebellar/tectal defects, axon disorganization, and motor decline. - Quantifiable disease biomarkers include SCMAS accumulation, hypertrophic/enlarged lysosomes, localized TUNEL-positive apoptosis, reduced proliferation in retina and midbrain-hindbrain boundary, and seizure-like hyperactivity preceding motor failure. - Survival is markedly shortened: mutants die around 5 dpf in the main phenotype summary, with survival curves showing death by about 8 dpf.	(mahmood2013azebrafishmodel pages 2-3, kiani2025wholeorganismscreeningin pages 1-6, mahmood2013azebrafishmodel pages 16-17, mahmood2013azebrafishmodel pages 1-2, mahmood2013azebrafishmodel media 97a62347)
Assays	- Enzyme assay conditions in zebrafish embryos: homogenates in acidic buffer (150 mM NaCl, 100 mM sodium citrate, 1 g/L Triton X-100, pH 4.0); 6 µg crude protein incubated with 0.25 mM Arg-Ala-Phe-ACC in 50 µL for 90 min. - Additional functional/pathology assays: RT-PCR genotyping/splice analysis, Western blot, anti-TPP1 immunofluorescence, LysoTracker for lysosomal enlargement, SCMAS staining, TUNEL, and automated locomotor tracking. - Recent zebrafish screening work adds Lamp1 lysosomal reporters, EEG for epileptiform activity, RNA-seq, and high-content imaging.	(mahmood2013azebrafishmodel pages 5-6, mahmood2013azebrafishmodel pages 3-4, kiani2025wholeorganismscreeningin pages 1-6, mahmood2013azebrafishmodel media 97a62347)
Applications / therapeutics	- Zebrafish tpp1 mutants are used as a CLN2/Batten disease model for mechanistic study and whole-organism drug screening because early seizure-like and neurodegenerative phenotypes are machine-quantifiable. - A 640-compound zebrafish screen identified pregnenolone as a candidate that suppresses seizures and cell death and improves lysosomal architecture (preprint evidence). - In human CLN2 translational work, CNS-directed cerliponase alfa slows neurologic decline but does not adequately prevent retinal degeneration; a first-in-human retinal approach used intravitreal rhTPP1 0.2 mg in 0.05 mL, unilateral, every 8 weeks / over 12–18 months in 8 children.	(kiani2025wholeorganismscreeningin pages 1-6, wawrzynski2024firstinman pages 1-2, wawrzynski2024firstinman pages 2-3, sampaio2023clinicalmanagementand pages 1-2, takahashi2024investigatingtheinvolvement pages 16-20)
Key quantitative data	- Identity/structure: 62% identity, 67% homology to human TPP1; 557 aa protein; 13 exons; 19 aa signal peptide; mature human/vertebrate TPP1 half-life reported as ~20 h. - Zebrafish phenotype timing: pathology detectable from 2 dpf in later work; progressive eye defects by larval stages; death by 5–8 dpf depending on readout/study panel. - Human therapeutic numbers: intravitreal rhTPP1 trial enrolled 8 children aged 5–9 years; PMV decline in progressing patients averaged 0.168 mm3/yr treated vs 0.254 mm3/yr untreated; cerliponase alfa safety data in 38 children showed convulsion-related events in 31/38 (82%), only 4% considered drug-related, and hypersensitivity in 19/38 (50%) with 6 grade-3 reactions.	(mahmood2013azebrafishmodel pages 2-2, mahmood2013azebrafishmodel pages 16-17, wawrzynski2024firstinman pages 1-2, wawrzynski2024firstinman pages 2-3, ammendolia2024adversereactionsto pages 7-10)

Table: This table condenses the most relevant functional annotation points for Danio rerio tpp1/TPP1, including enzyme function, lysosomal localization, zebrafish loss-of-function phenotypes, assays, and translational therapeutic context. It is useful as a quick evidence-linked summary for annotation and disease-model interpretation.

Key sources (with URLs and publication dates)

Mahmood F. et al. Brain (May 2013). “A zebrafish model of CLN2 disease is deficient in tripeptidyl peptidase 1…” https://doi.org/10.1093/brain/awt043 (mahmood2013azebrafishmodel pages 2-3)
de Brito Sampaio L.P. et al. Arquivos de Neuro-Psiquiatria (Mar 2023). “Clinical management and diagnosis of CLN2 disease: consensus…” https://doi.org/10.1055/s-0043-1761434 (sampaio2023clinicalmanagementand pages 1-2)
Ammendolia I. et al. Pharmaceuticals (Nov 2024). “Adverse Reactions to… Cerliponase Alfa…” https://doi.org/10.3390/ph17111513 (ammendolia2024adversereactionsto pages 7-10)
Wawrzynski J. et al. Eye (Dec 2024). “First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy” https://doi.org/10.1038/s41433-023-02859-4 (wawrzynski2024firstinman pages 1-2)

Limitations of the available evidence for Danio rerio tpp1

Direct zebrafish molecular-biochemistry literature for Tpp1 (e.g., detailed physiological substrates beyond model fluorogenic substrates) remains relatively sparse in the retrieved corpus, and much mechanistic detail is derived from vertebrate TPP1 knowledge summarized within the zebrafish CLN2 model paper. (mahmood2013azebrafishmodel pages 2-3, mahmood2013azebrafishmodel pages 3-4)

References

(mahmood2013azebrafishmodel pages 2-2): Fahad Mahmood, Sonia Fu, Jennifer Cooke, Stephen W. Wilson, Jonathan D. Cooper, and Claire Russell. A zebrafish model of cln2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain : a journal of neurology, 136 Pt 5:1488-507, May 2013. URL: https://doi.org/10.1093/brain/awt043, doi:10.1093/brain/awt043. This article has 81 citations.
(mahmood2013azebrafishmodel pages 2-3): Fahad Mahmood, Sonia Fu, Jennifer Cooke, Stephen W. Wilson, Jonathan D. Cooper, and Claire Russell. A zebrafish model of cln2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain : a journal of neurology, 136 Pt 5:1488-507, May 2013. URL: https://doi.org/10.1093/brain/awt043, doi:10.1093/brain/awt043. This article has 81 citations.
(mahmood2013azebrafishmodel pages 5-6): Fahad Mahmood, Sonia Fu, Jennifer Cooke, Stephen W. Wilson, Jonathan D. Cooper, and Claire Russell. A zebrafish model of cln2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain : a journal of neurology, 136 Pt 5:1488-507, May 2013. URL: https://doi.org/10.1093/brain/awt043, doi:10.1093/brain/awt043. This article has 81 citations.
(mahmood2013azebrafishmodel pages 3-4): Fahad Mahmood, Sonia Fu, Jennifer Cooke, Stephen W. Wilson, Jonathan D. Cooper, and Claire Russell. A zebrafish model of cln2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain : a journal of neurology, 136 Pt 5:1488-507, May 2013. URL: https://doi.org/10.1093/brain/awt043, doi:10.1093/brain/awt043. This article has 81 citations.
(mahmood2013azebrafishmodel pages 16-17): Fahad Mahmood, Sonia Fu, Jennifer Cooke, Stephen W. Wilson, Jonathan D. Cooper, and Claire Russell. A zebrafish model of cln2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain : a journal of neurology, 136 Pt 5:1488-507, May 2013. URL: https://doi.org/10.1093/brain/awt043, doi:10.1093/brain/awt043. This article has 81 citations.
(mahmood2013azebrafishmodel pages 1-2): Fahad Mahmood, Sonia Fu, Jennifer Cooke, Stephen W. Wilson, Jonathan D. Cooper, and Claire Russell. A zebrafish model of cln2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain : a journal of neurology, 136 Pt 5:1488-507, May 2013. URL: https://doi.org/10.1093/brain/awt043, doi:10.1093/brain/awt043. This article has 81 citations.
(mahmood2013azebrafishmodel media 97a62347): Fahad Mahmood, Sonia Fu, Jennifer Cooke, Stephen W. Wilson, Jonathan D. Cooper, and Claire Russell. A zebrafish model of cln2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain : a journal of neurology, 136 Pt 5:1488-507, May 2013. URL: https://doi.org/10.1093/brain/awt043, doi:10.1093/brain/awt043. This article has 81 citations.
(mahmood2013azebrafishmodel media a79a33ad): Fahad Mahmood, Sonia Fu, Jennifer Cooke, Stephen W. Wilson, Jonathan D. Cooper, and Claire Russell. A zebrafish model of cln2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain : a journal of neurology, 136 Pt 5:1488-507, May 2013. URL: https://doi.org/10.1093/brain/awt043, doi:10.1093/brain/awt043. This article has 81 citations.
(mahmood2013azebrafishmodel media e597a90c): Fahad Mahmood, Sonia Fu, Jennifer Cooke, Stephen W. Wilson, Jonathan D. Cooper, and Claire Russell. A zebrafish model of cln2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain : a journal of neurology, 136 Pt 5:1488-507, May 2013. URL: https://doi.org/10.1093/brain/awt043, doi:10.1093/brain/awt043. This article has 81 citations.
(mahmood2013azebrafishmodel media 008308d6): Fahad Mahmood, Sonia Fu, Jennifer Cooke, Stephen W. Wilson, Jonathan D. Cooper, and Claire Russell. A zebrafish model of cln2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain : a journal of neurology, 136 Pt 5:1488-507, May 2013. URL: https://doi.org/10.1093/brain/awt043, doi:10.1093/brain/awt043. This article has 81 citations.
(takahashi2024investigatingtheinvolvement pages 16-20): Investigating the Involvement of GABAergic Interneurons and a Gene Therapy Strategy for Epilepsy in CLN2 Disease This article has 0 citations.
(wawrzynski2024firstinman pages 1-2): James Wawrzynski, Ana Rodriguez Martinez, Dorothy Ann Thompson, Dipak Ram, Richard Bowman, Rebecca Whiteley, Chin Gan, Louise Harding, Amanda Mortensen, Philippa Mills, Paul Gissen, and Robert H. Henderson. First in man study of intravitreal tripeptidyl peptidase 1 for cln2 retinopathy. Eye, 38:1176-1182, Dec 2024. URL: https://doi.org/10.1038/s41433-023-02859-4, doi:10.1038/s41433-023-02859-4. This article has 8 citations and is from a peer-reviewed journal.
(wawrzynski2024firstinman pages 2-3): James Wawrzynski, Ana Rodriguez Martinez, Dorothy Ann Thompson, Dipak Ram, Richard Bowman, Rebecca Whiteley, Chin Gan, Louise Harding, Amanda Mortensen, Philippa Mills, Paul Gissen, and Robert H. Henderson. First in man study of intravitreal tripeptidyl peptidase 1 for cln2 retinopathy. Eye, 38:1176-1182, Dec 2024. URL: https://doi.org/10.1038/s41433-023-02859-4, doi:10.1038/s41433-023-02859-4. This article has 8 citations and is from a peer-reviewed journal.
(sampaio2023clinicalmanagementand pages 1-2): Leticia Pereira de Brito Sampaio, Maria Luiza Giraldes de Manreza, André Pessoa, Juliana Gurgel-Giannetti, Ana Carolina Coan, Hélio van der Linden Júnior, Emília Katiane Embiruçu, Adélia Maria de Miranda Henriques-Souza, and Fernando Kok. Clinical management and diagnosis of cln2 disease: consensus of the brazilian experts group. Arquivos de Neuro-Psiquiatria, 81:284-295, Mar 2023. URL: https://doi.org/10.1055/s-0043-1761434, doi:10.1055/s-0043-1761434. This article has 16 citations and is from a peer-reviewed journal.
(sampaio2023clinicalmanagementand pages 6-7): Leticia Pereira de Brito Sampaio, Maria Luiza Giraldes de Manreza, André Pessoa, Juliana Gurgel-Giannetti, Ana Carolina Coan, Hélio van der Linden Júnior, Emília Katiane Embiruçu, Adélia Maria de Miranda Henriques-Souza, and Fernando Kok. Clinical management and diagnosis of cln2 disease: consensus of the brazilian experts group. Arquivos de Neuro-Psiquiatria, 81:284-295, Mar 2023. URL: https://doi.org/10.1055/s-0043-1761434, doi:10.1055/s-0043-1761434. This article has 16 citations and is from a peer-reviewed journal.
(sampaio2023clinicalmanagementand pages 3-6): Leticia Pereira de Brito Sampaio, Maria Luiza Giraldes de Manreza, André Pessoa, Juliana Gurgel-Giannetti, Ana Carolina Coan, Hélio van der Linden Júnior, Emília Katiane Embiruçu, Adélia Maria de Miranda Henriques-Souza, and Fernando Kok. Clinical management and diagnosis of cln2 disease: consensus of the brazilian experts group. Arquivos de Neuro-Psiquiatria, 81:284-295, Mar 2023. URL: https://doi.org/10.1055/s-0043-1761434, doi:10.1055/s-0043-1761434. This article has 16 citations and is from a peer-reviewed journal.
(sampaio2023clinicalmanagementand pages 10-11): Leticia Pereira de Brito Sampaio, Maria Luiza Giraldes de Manreza, André Pessoa, Juliana Gurgel-Giannetti, Ana Carolina Coan, Hélio van der Linden Júnior, Emília Katiane Embiruçu, Adélia Maria de Miranda Henriques-Souza, and Fernando Kok. Clinical management and diagnosis of cln2 disease: consensus of the brazilian experts group. Arquivos de Neuro-Psiquiatria, 81:284-295, Mar 2023. URL: https://doi.org/10.1055/s-0043-1761434, doi:10.1055/s-0043-1761434. This article has 16 citations and is from a peer-reviewed journal.
(ammendolia2024adversereactionsto pages 7-10): Ilaria Ammendolia, Maria Sframeli, Emanuela Esposito, Luigi Cardia, Alberto Noto, Mariaconcetta Currò, Gioacchino Calapai, Maria De Pasquale, Carmen Mannucci, and Fabrizio Calapai. Adverse reactions to the orphan drug cerliponase alfa in the treatment of neurolipofuscinosis type 2 (cln2). Pharmaceuticals, 17:1513, Nov 2024. URL: https://doi.org/10.3390/ph17111513, doi:10.3390/ph17111513. This article has 3 citations.
(kiani2025wholeorganismscreeningin pages 1-6): Lisa N. Kiani, Gabriele Civiletto, Giulia Lizzo, Anselm Zdebik, Gini Brickell, Fahad Mahmood, Dionysios D. Nalkos, Lucas Michaelides, Philip Eldridge, Emily M. Young, Hazel McPherson, Michelangelo Campanella, Philipp Gut, and Claire Russell. Whole-organism screening in a zebrafish model of cln2 disease identifies pregnenolone as a modulator of lysosomal functions with anti-epileptic properties. BioRxiv, Aug 2025. URL: https://doi.org/10.1101/2025.08.26.670480, doi:10.1101/2025.08.26.670480. This article has 0 citations.

Artifacts

Edison artifact artifact-00

Citations

mahmood2013azebrafishmodel pages 2-3
mahmood2013azebrafishmodel pages 2-2
mahmood2013azebrafishmodel pages 3-4
mahmood2013azebrafishmodel pages 5-6
takahashi2024investigatingtheinvolvement pages 16-20
ammendolia2024adversereactionsto pages 7-10
wawrzynski2024firstinman pages 2-3
sampaio2023clinicalmanagementand pages 1-2
wawrzynski2024firstinman pages 1-2
mahmood2013azebrafishmodel pages 16-17
mahmood2013azebrafishmodel pages 1-2
sampaio2023clinicalmanagementand pages 6-7
sampaio2023clinicalmanagementand pages 3-6
sampaio2023clinicalmanagementand pages 10-11
kiani2025wholeorganismscreeningin pages 1-6
https://doi.org/10.1093/brain/awt043
https://doi.org/10.1055/s-0043-1761434
https://doi.org/10.3390/ph17111513
https://doi.org/10.1038/s41433-023-02859-4
https://doi.org/10.1093/brain/awt043,
https://doi.org/10.1038/s41433-023-02859-4,
https://doi.org/10.1055/s-0043-1761434,
https://doi.org/10.3390/ph17111513,
https://doi.org/10.1101/2025.08.26.670480,

📚 Additional Documentation

Notes

(tpp1-notes.md)

tpp1 review notes

Curated in DANRE batch 04. Tpp1 has a clear lysosomal tripeptidyl-peptidase core function. I kept CNS development, neurogenesis, and locomotory behavior as non-core phenotypes from the zebrafish CLN2 model rather than treating them as the gene product activity PMID:23587805.
Follow-up: broad endopeptidase activity is now non-core because tripeptidyl-peptidase activity is the informative function.

📄 View Raw YAML

id: F8W2M8
gene_symbol: tpp1
product_type: PROTEIN
status: DRAFT
taxon:
  id: NCBITaxon:7955
  label: Danio rerio
description: tpp1 encodes lysosomal tripeptidyl-peptidase 1, a serine peptidase that releases N-terminal tripeptides during
  lysosomal proteolysis. The core function is lysosomal tripeptidyl-peptidase/proteolysis activity; neurodevelopmental, neurodegeneration,
  and locomotor phenotypes are retained as non-core consequences of Tpp1 deficiency.
existing_annotations:
- term:
    id: GO:0006508
    label: proteolysis
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: |-
      proteolysis (GO:0006508) is supported for Tpp1. Falcon deep research confirms zebrafish Tpp1 is a lysosomal sedolisin-family serine protease contributing to lysosomal proteolysis/proteostasis.
    action: ACCEPT
    reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis.
    supported_by:
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Lysosomal serine protease with tripeptidyl-peptidase I
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Release of an N-terminal tripeptide
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
    - reference_id: PMID:23587805
      supporting_text: deficient in tripeptidyl peptidase 1
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: Tpp1 contributes to **lysosomal proteolysis/proteostasis**
- term:
    id: GO:0008240
    label: tripeptidyl-peptidase activity
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: |-
      tripeptidyl-peptidase activity (GO:0008240) is supported for Tpp1 and is its core molecular function. Falcon deep research confirms zebrafish Tpp1 acts mainly as an N-terminal exopeptidase releasing tripeptides, assayed with the fluorogenic substrate Arg-Ala-Phe-ACC at acidic pH.
    action: ACCEPT
    reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis.
    supported_by:
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Lysosomal serine protease with tripeptidyl-peptidase I
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Release of an N-terminal tripeptide
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
    - reference_id: PMID:23587805
      supporting_text: deficient in tripeptidyl peptidase 1
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: tpp1 encodes lysosomal tripeptidyl-peptidase 1 (EC 3.4.14.9), a sedolisin-family serine protease that acts mainly as an **N-terminal exopeptidase**
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: cleavage of the fluorogenic tripeptidyl substrate **Arg-Ala-Phe-ACC** at **acidic pH (pH 4.0)**
- term:
    id: GO:0004175
    label: endopeptidase activity
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: |-
      endopeptidase activity (GO:0004175) is a supported but broad parent term for Tpp1. Falcon deep research confirms Tpp1 acts mainly as an N-terminal exopeptidase with only limited endopeptidase activity, so this broad term is retained as non-core.
    action: KEEP_AS_NON_CORE
    reason: The more informative tripeptidyl-peptidase and serine-type peptidase activities are reviewed separately; this
      parent term is retained as non-core to reduce redundancy.
    supported_by:
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Lysosomal serine protease with tripeptidyl-peptidase I
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Release of an N-terminal tripeptide
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
    - reference_id: PMID:23587805
      supporting_text: deficient in tripeptidyl peptidase 1
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: removing **tripeptides** from the N-termini of polypeptide substrates, with some **limited endopeptidase activity**
- term:
    id: GO:0007417
    label: central nervous system development
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: |-
      central nervous system development (GO:0007417) is supported as a phenotype of Tpp1 deficiency but is not the core molecular role. Falcon deep research describes early-onset progressive neurodegeneration of the retina, optic tectum and cerebellum in tpp1 mutants, consistent with a downstream consequence of impaired lysosomal proteolysis.
    action: KEEP_AS_NON_CORE
    reason: The direct conserved role is lysosomal tripeptidyl-peptidase/proteolysis; neurodevelopmental and locomotor defects
      are downstream phenotypes.
    supported_by:
    - reference_id: PMID:23587805
      supporting_text: displays progressive neurodegeneration
    - reference_id: PMID:23587805
      supporting_text: functional motor impairment
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: early-onset, progressive neurodegenerative phenotype with prominent defects in **retina**, **optic tectum**, and **cerebellum**
- term:
    id: GO:0004252
    label: serine-type endopeptidase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: |-
      serine-type endopeptidase activity (GO:0004252) is a broad term for Tpp1 that asserts endopeptidase specificity. Falcon deep research confirms Tpp1 is a serine protease with a sedolisin-family catalytic triad (Glu-Asp-Ser), but it acts mainly as an N-terminal exopeptidase with only limited endopeptidase activity. This IEA annotation derives from the Peptidase_S8/S53 superfamily fold (InterPro IPR036852), which spans both endo- and exo-peptidases, so the automatic domain mapping does not accurately reflect CLN2/Tpp1's primary exopeptidase specificity. The serine-type peptidase activity (GO:0008236) parent is more accurate, and the specific tripeptidyl-peptidase activity (GO:0008240) is the core function. Retained as non-core, consistent with the endopeptidase activity (GO:0004175) parent term.
    action: KEEP_AS_NON_CORE
    reason: Tpp1 is primarily an exopeptidase with only limited endopeptidase activity; this endopeptidase-specific IEA term
      (from the broad Peptidase_S8/S53 fold) overstates the specificity and is retained as non-core, consistent with the GO:0004175
      endopeptidase activity parent.
    supported_by:
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Lysosomal serine protease with tripeptidyl-peptidase I
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Release of an N-terminal tripeptide
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
    - reference_id: PMID:23587805
      supporting_text: deficient in tripeptidyl peptidase 1
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: removing **tripeptides** from the N-termini of polypeptide substrates, with some **limited endopeptidase activity**
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: catalytic triad consistent with sedolisin-family enzymes (reported as **Glu–Asp–Ser**
- term:
    id: GO:0005764
    label: lysosome
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: |-
      lysosome (GO:0005764) is supported for Tpp1. Falcon deep research confirms the enzyme is targeted to and functions in the lysosome, predicted to be delivered after removal of a 19-aa signal peptide via the mannose-6-phosphate pathway.
    action: ACCEPT
    reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis.
    supported_by:
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Lysosomal serine protease with tripeptidyl-peptidase I
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Release of an N-terminal tripeptide
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
    - reference_id: PMID:23587805
      supporting_text: deficient in tripeptidyl peptidase 1
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: the enzyme is targeted to and functions in the **lysosome**
- term:
    id: GO:0006508
    label: proteolysis
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: |-
      proteolysis (GO:0006508) is supported for Tpp1 (InterPro-derived). Falcon deep research confirms Tpp1 contributes to lysosomal proteolysis/proteostasis; loss yields lysosomal storage of undegraded material. Note that the more specific GO:1905146 (lysosomal protein catabolic process) would more precisely capture Tpp1's biological role within the lysosome; GO:0006508 is retained here as the directly annotated, conservative term.
    action: ACCEPT
    reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis.
    supported_by:
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Lysosomal serine protease with tripeptidyl-peptidase I
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Release of an N-terminal tripeptide
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
    - reference_id: PMID:23587805
      supporting_text: deficient in tripeptidyl peptidase 1
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: Tpp1 contributes to **lysosomal proteolysis/proteostasis**
- term:
    id: GO:0008236
    label: serine-type peptidase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: |-
      serine-type peptidase activity (GO:0008236) is correct but less specific than tripeptidyl-peptidase activity. Falcon deep research confirms the informative function is N-terminal tripeptidyl exopeptidase cleavage, so the more specific GO:0008240 is preferred.
    action: MODIFY
    reason: The specific molecular function is tripeptidyl-peptidase activity.
    proposed_replacement_terms:
    - id: GO:0008240
      label: tripeptidyl-peptidase activity
    supported_by:
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Lysosomal serine protease with tripeptidyl-peptidase I
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Release of an N-terminal tripeptide
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
    - reference_id: PMID:23587805
      supporting_text: deficient in tripeptidyl peptidase 1
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: tpp1 encodes lysosomal tripeptidyl-peptidase 1 (EC 3.4.14.9), a sedolisin-family serine protease that acts mainly as an **N-terminal exopeptidase**
- term:
    id: GO:0005764
    label: lysosome
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: |-
      lysosome (GO:0005764) is supported for Tpp1 by orthology to human TPP1/O14773. Falcon deep research corroborates lysosomal localization, with loss producing enlarged/hypertrophic lysosomes and SCMAS storage.
    action: ACCEPT
    reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis.
    supported_by:
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Lysosomal serine protease with tripeptidyl-peptidase I
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Release of an N-terminal tripeptide
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
    - reference_id: PMID:23587805
      supporting_text: deficient in tripeptidyl peptidase 1
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: lysosomal storage phenotypes including **enlarged/hypertrophic lysosomes**
- term:
    id: GO:0007417
    label: central nervous system development
  evidence_type: IMP
  original_reference_id: PMID:23587805
  review:
    summary: |-
      central nervous system development (GO:0007417) is supported as a phenotype of Tpp1 deficiency (zebrafish IMP) but is not the core molecular role. Falcon deep research describes progressive neurodegeneration of the retina, optic tectum and cerebellum in tpp1 mutants.
    action: KEEP_AS_NON_CORE
    reason: The direct conserved role is lysosomal tripeptidyl-peptidase/proteolysis; neurodevelopmental and locomotor defects
      are downstream phenotypes.
    supported_by:
    - reference_id: PMID:23587805
      supporting_text: displays progressive neurodegeneration
    - reference_id: PMID:23587805
      supporting_text: functional motor impairment
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: early-onset, progressive neurodegenerative phenotype with prominent defects in **retina**, **optic tectum**, and **cerebellum**
- term:
    id: GO:0007626
    label: locomotory behavior
  evidence_type: IMP
  original_reference_id: PMID:23587805
  review:
    summary: |-
      locomotory behavior (GO:0007626) is supported as a phenotype of Tpp1 deficiency (zebrafish IMP) but is not the core molecular role. Falcon deep research notes a phase of increased locomotion consistent with seizures followed by progressive motor impairment.
    action: KEEP_AS_NON_CORE
    reason: The direct conserved role is lysosomal tripeptidyl-peptidase/proteolysis; neurodevelopmental and locomotor defects
      are downstream phenotypes.
    supported_by:
    - reference_id: PMID:23587805
      supporting_text: displays progressive neurodegeneration
    - reference_id: PMID:23587805
      supporting_text: functional motor impairment
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: phase of **increased locomotion consistent with seizures**
- term:
    id: GO:0022008
    label: neurogenesis
  evidence_type: IMP
  original_reference_id: PMID:23587805
  review:
    summary: |-
      neurogenesis (GO:0022008) is supported as a phenotype of Tpp1 deficiency (zebrafish IMP) but is not the core molecular role. PMID:23587805 reports that secondary neurogenesis in the retina, optic tectum and cerebellum is impaired in tpp1 mutant zebrafish, and falcon deep research notes a sustained reduction in proliferation affecting the retina and midbrain-hindbrain boundary.
    action: KEEP_AS_NON_CORE
    reason: The direct conserved role is lysosomal tripeptidyl-peptidase/proteolysis; neurodevelopmental and locomotor defects
      are downstream phenotypes.
    supported_by:
    - reference_id: PMID:23587805
      supporting_text: Secondary neurogenesis in the
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: '**sustained reduction in proliferation**'
- term:
    id: GO:0008240
    label: tripeptidyl-peptidase activity
  evidence_type: ISS
  original_reference_id: PMID:14609438
  review:
    summary: |-
      tripeptidyl-peptidase activity (GO:0008240) is supported for Tpp1 by sequence similarity to the highly conserved sedolisin-family CLN2/TPP-I enzymes. Falcon deep research confirms zebrafish Tpp1 acts mainly as an N-terminal exopeptidase releasing tripeptides.
    action: ACCEPT
    reason: Tpp1 is a lysosomal serine tripeptidyl-peptidase acting in proteolysis.
    supported_by:
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Lysosomal serine protease with tripeptidyl-peptidase I
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: Release of an N-terminal tripeptide
    - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
    - reference_id: PMID:23587805
      supporting_text: deficient in tripeptidyl peptidase 1
    - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
      supporting_text: removing **tripeptides** from the N-termini of polypeptide substrates, with some **limited endopeptidase activity**
references:
- id: GO_REF:0000002
  title: Gene Ontology annotation through association of InterPro records with GO terms
  findings: []
- id: GO_REF:0000024
  title: Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence
    similarity
  findings: []
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
  findings: []
- id: GO_REF:0000044
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative
    changes to GO terms applied by UniProt
  findings: []
- id: PMID:14609438
  title: A model of tripeptidyl-peptidase I (CLN2), a ubiquitous and highly conserved member of the sedolisin family of serine-carboxyl
    peptidases.
  findings:
  - statement: |-
      TPP-I/CLN2 is a member of the sedolisin family of serine-carboxyl peptidases, and its loss causes a fatal neurodegenerative disease (late-infantile neuronal ceroid lipofuscinosis).
    supporting_text: defects in expression of this enzyme lead to a fatal neurodegenerative disease
    reference_section_type: ABSTRACT
  - statement: |-
      CLN2 orthologs are highly conserved and widely distributed across eukaryotes, including closely related but distinct enzymes present in fish such as zebrafish.
    supporting_text: Closely related, although clearly distinct, enzymes are present in fish
    reference_section_type: ABSTRACT
- id: PMID:23587805
  title: A zebrafish model of CLN2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration
    accompanied by a reduction in proliferation.
  findings:
  - statement: |-
      Homozygous tpp1(sa0011) mutant zebrafish are deficient in tripeptidyl peptidase 1 and display a severe, progressive, early onset neurodegenerative phenotype.
    supporting_text: deficient in tripeptidyl peptidase 1 and
    reference_section_type: ABSTRACT
  - statement: |-
      As in human CLN2 patients, the mutant zebrafish store subunit c of mitochondrial ATP-synthase and develop hypertrophic lysosomes with localized apoptotic cell death in the retina, optic tectum and cerebellum.
    supporting_text: storage of subunit c
    reference_section_type: ABSTRACT
  - statement: |-
      Secondary neurogenesis in the retina, optic tectum and cerebellum is impaired in tpp1 mutant zebrafish.
    supporting_text: Secondary neurogenesis in the
    reference_section_type: ABSTRACT
  - statement: |-
      The neurodegenerative phenotype results in functional motor impairment preceded by a phase of seizure-like hyperactivity.
    supporting_text: functional motor impairment
    reference_section_type: ABSTRACT
- id: file:DANRE/tpp1/tpp1-uniprot.txt
  title: UniProtKB entry F8W2M8 for Danio rerio tpp1
  findings:
  - statement: |-
      UniProt describes Tpp1 as a lysosomal serine protease with tripeptidyl-peptidase I activity that releases an N-terminal tripeptide from a polypeptide but also has endopeptidase activity (EC 3.4.14.9).
    supporting_text: Lysosomal serine protease with tripeptidyl-peptidase I
    reference_section_type: DATABASE_ENTRY
  - statement: |-
      Tpp1 is localized to the lysosome and is activated by autocatalytic proteolytic processing from a precursor zymogen.
    supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
    reference_section_type: DATABASE_ENTRY
- id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
  title: Falcon deep research synthesis for Danio rerio tpp1 (tripeptidyl-peptidase 1 / CLN2)
  findings:
  - statement: |-
      Zebrafish tpp1 encodes lysosomal tripeptidyl-peptidase 1 (EC 3.4.14.9), a sedolisin (S53)-family serine protease that acts mainly as an N-terminal exopeptidase releasing tripeptides, with limited endopeptidase activity.
    supporting_text: tpp1 encodes lysosomal tripeptidyl-peptidase 1 (EC 3.4.14.9), a sedolisin-family serine protease that acts mainly as an **N-terminal exopeptidase**
    reference_section_type: OTHER
  - statement: |-
      The TPP1 catalytic triad is consistent with sedolisin-family enzymes, reported as Glu-Asp-Ser, distinguishing it from classical Ser-His-Asp serine proteases.
    supporting_text: catalytic triad consistent with sedolisin-family enzymes (reported as **Glu–Asp–Ser**
    reference_section_type: OTHER
  - statement: |-
      Zebrafish Tpp1 is predicted to be targeted to the lysosome after removal of a 19-aa signal peptide and is trafficked to lysosomes via the mannose-6-phosphate pathway.
    supporting_text: predicted to be targeted to the lysosome after removal of a 19-aa signal peptide
    reference_section_type: OTHER
  - statement: |-
      Tpp1 activity in zebrafish embryos is measured as cleavage of the fluorogenic tripeptidyl substrate Arg-Ala-Phe-ACC at acidic pH (pH 4.0), consistent with a lysosomal enzyme, and is significantly reduced in tpp1(sa0011) mutants.
    supporting_text: cleavage of the fluorogenic tripeptidyl substrate **Arg-Ala-Phe-ACC** at **acidic pH (pH 4.0)**
    reference_section_type: OTHER
  - statement: |-
      Loss of Tpp1 produces classic lysosomal storage phenotypes including enlarged/hypertrophic lysosomes and accumulation of subunit c of mitochondrial ATP synthase (SCMAS), positioning Tpp1 within lysosome-dependent proteostasis and degradative pathways.
    supporting_text: lysosomal storage phenotypes including **enlarged/hypertrophic lysosomes**
    reference_section_type: OTHER
  - statement: |-
      Homozygous tpp1(sa0011) mutants show an early-onset, progressive neurodegenerative phenotype with defects in retina, optic tectum and cerebellum, increased apoptosis, sustained reduction in proliferation, seizure-like hyperactivity, and motor decline.
    supporting_text: early-onset, progressive neurodegenerative phenotype with prominent defects in **retina**, **optic tectum**, and **cerebellum**
    reference_section_type: OTHER
core_functions:
- description: tpp1 acts in the lysosome as tripeptidyl-peptidase 1, releasing N-terminal tripeptides during lysosomal protein
    catabolism.
  molecular_function:
    id: GO:0008240
    label: tripeptidyl-peptidase activity
  directly_involved_in:
  - id: GO:0006508
    label: proteolysis
  locations:
  - id: GO:0005764
    label: lysosome
  supported_by:
  - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
    supporting_text: Lysosomal serine protease with tripeptidyl-peptidase I
  - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
    supporting_text: Release of an N-terminal tripeptide
  - reference_id: file:DANRE/tpp1/tpp1-uniprot.txt
    supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
  - reference_id: PMID:23587805
    supporting_text: deficient in tripeptidyl peptidase 1
  - reference_id: file:DANRE/tpp1/tpp1-deep-research-falcon.md
    supporting_text: tpp1 encodes lysosomal tripeptidyl-peptidase 1 (EC 3.4.14.9), a sedolisin-family serine protease that acts mainly as an **N-terminal exopeptidase**
suggested_questions:
- question: Which endogenous lysosomal substrates require zebrafish Tpp1-mediated removal of N-terminal tripeptides, and which
    accumulate as storage material when the enzyme is absent?
- question: Does zebrafish Tpp1 require autocatalytic activation of its zymogen at acidic lysosomal pH, mirroring the proenzyme
    maturation described for mammalian TPP-I/CLN2?
- question: To what extent do the neurodegenerative and locomotor phenotypes of Tpp1-deficient zebrafish stem from impaired
    lysosomal proteolysis versus secondary consequences of ceroid-lipofuscin storage?
suggested_experiments:
- hypothesis: Loss of zebrafish tpp1 abolishes lysosomal tripeptidyl-peptidase activity and leads to accumulation of autofluorescent
    storage material in neurons.
  description: Generate a tpp1 null line by CRISPR/Cas9, then assay lysosomal tripeptidyl-peptidase activity in larval/adult
    brain lysates against a fluorogenic Ala-Ala-Phe substrate and quantify ceroid-lipofuscin storage histologically.
  experiment_type: CRISPR knockout
- hypothesis: Recombinant zebrafish Tpp1 is produced as an inactive zymogen that undergoes autocatalytic activation upon exposure
    to acidic pH.
  description: Express and purify the Tpp1 proenzyme, incubate across a range of pH values (acidic lysosomal versus neutral),
    and monitor proteolytic processing and gain of exopeptidase activity over time by SDS-PAGE and activity assays.
  experiment_type: tripeptidyl-peptidase activity assay
- hypothesis: Restoring Tpp1 enzymatic activity in tpp1-deficient zebrafish rescues neurodegeneration and locomotor defects.
  description: Reintroduce wild-type or catalytically dead tpp1 mRNA/transgene into tpp1 mutants and assess rescue of progressive
    neurodegeneration, neuronal proliferation, and swimming behavior alongside lipofuscin storage load.
  experiment_type: lipofuscin/storage-material histology

tpp1

Gene Description

Existing Annotations Review

Core Functions

tpp1 acts in the lysosome as tripeptidyl-peptidase 1, releasing N-terminal tripeptides during lysosomal protein catabolism.

References

Suggested Questions for Experts

Suggested Experiments

Deep Research

Falcon

Research Report: Functional Annotation of tpp1 (UniProt F8W2M8) in Danio rerio (zebrafish)

0) Target verification (critical disambiguation)

1) Key concepts and definitions (current understanding)

1.1 What TPP1 is

1.2 Enzyme classification and catalytic mechanism

1.3 Processing, maturation, and lysosomal targeting

2) Zebrafish tpp1 molecular function and evidence (biochemistry-oriented)

2.1 Substrate specificity and how it is measured experimentally in zebrafish

2.2 Evidence of loss-of-function in zebrafish mutants

3) Cellular localization and pathway context in zebrafish

3.1 Subcellular site of action

3.2 Pathway context: lysosomal proteostasis and storage pathology

4) Zebrafish loss-of-function phenotypes (organism-level functional annotation)

4.1 Neurodegeneration and retinal degeneration

4.2 Cell death and reduced proliferation

4.3 Axon tract and motor phenotypes; seizure-like behavior

4.4 Survival statistics (zebrafish)

Visual evidence from the primary zebrafish paper

5) Current applications and real-world implementations

5.1 Zebrafish as a disease-model platform for CLN2/TPP1 biology

5.2 Clinical implementation: enzyme replacement therapy for CLN2 (human translational context)

5.3 Addressing retinal disease: intravitreal rhTPP1 (2024)

6) Expert opinions / authoritative guidance (2023–2024 prioritized)

6.1 2023 Brazilian expert consensus (diagnosis and management)

6.2 Expert framing of ERT limitations

7) Relevant recent statistics and quantitative findings (recent studies emphasized)

7.1 Real-world safety signals for cerliponase alfa (2024)

7.2 Intravitreal rhTPP1 retinal outcomes (2024)

8) Summary interpretation for functional annotation (zebrafish-focused)

Evidence summary table

Key sources (with URLs and publication dates)

Limitations of the available evidence for Danio rerio tpp1

Artifacts

Citations

📚 Additional Documentation

Notes

tpp1 review notes

📄 View Raw YAML